Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the impact of sequential overlapping treatment with
PD-1 monoclonal antibody (mAb), pembrolizumab/MK-1375, followed by ibrutinib on endogenous
immune function in previously untreated, high-risk CLL patients. Immune function will be
evaluated through various laboratory correlative tests.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute